Equillium announces update on multi-cytokine inhibitors eq101 & eq102 in development for alopecia areata and celiac disease

La jolla, calif.--(business wire)---- $eq--equillium, inc. (nasdaq: eq), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced an update on multi-cytokine programs eq101 in development for the treatment of alopecia areata, eq102 in development for the treatment of celiac disease, and eq302, a new orally delivered multi-cytokine inhibitor. “we are pleased to have completed enrollment of the eq101 phase 2 stu.
EQ Ratings Summary
EQ Quant Ranking